Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602541 | 0.90 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3596504 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3607137 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3613868 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3607353 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL3596895 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14870451 | 0.85 | MAPT (0.43) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14155550 | 0.82 | NAMPT (0.54) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3613929 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL3596683 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | claimed |
| US-9358250-B2 | Methods of using SCD1 antagonists | GENENTECH, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9358250-B2 | Methods of using SCD1 antagonists | GENENTECH, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041696-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| WO-2008074824-A2 | ISOQUINOLINECARBOXAMIDES AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041696-A1 | Compounds | CYP11B2, SCD, CYP3A5 | SMN1; SMN2 618/4885MAPT 3377/4885CYP1A2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.